drugset
drugset / Trial / NCT04685473

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

NCT04685473 ↗

Phase 1 Completed 24 enrolled Taivex Therapeutics Corporation
NaSingle-groupOpen-labelTreatment

Summary

T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent anti-cancer agent in numerous human cancer cell lines. In addition, oral administration of T-1101 (Tosylate) showed tumor growth inhibition in different mouse xenograft models of human cancers. In this study, safety, tolerability and pharmacokinetic (PK) of T-1101 (Tosylate) capsules will be evaluated and also the recommended dose and regimen(s) to initiate Phase 2 will be determined.

Timeline

Start
2021-01-07
Primary completion
2025-04-11
Completion
2025-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject T-1101 Small molecule — Oral

Indications

refractory malignant neoplasm